13F-HR filed by Avoro Capital Advisors LLC
Avoro Capital Advisors LLC filed this 13F-HR for the quarter ended 2024-03-31, filed 2024-05-15, with 46 holding rows worth $8,573,512,829.
- Accession
- 0001104659-24-061613
- Filer
- CIK 1633313
- Filed
- 2024-05-15
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q1 2024
A holdings report, 46 entries on the cover page, a total value of $8,573,512,829 stated on the cover page (in dollars after the unit check, H1), rows summing to $8,573,512,829 with VALUE read as dollars as filed, 13F file number 028-16573. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL COM | 91307C102 | Stock | 2,858,888 | $656,743,751 | dollars as filed | |
| APELLIS PHARMACEUTICALS INC | 03753U106 | COM | 11,111,111 | $653,111,105 | dollars as filed | |
| ASCENDIS PHARMA A/S DKK 1.0 AD | 04351P101 | SPONSORED ADR | 3,966,666 | $599,640,899 | dollars as filed | |
| SAREPTA THERAPEUTICS INC | 803607100 | COM | 4,344,444 | $562,431,720 | dollars as filed | |
| MADRIGAL PHARMACEUTICALS INC COM | 558868105 | Stock | 1,944,444 | $519,244,326 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 1,238,467 | $487,609,227 | dollars as filed | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 2,555,555 | $454,709,901 | dollars as filed | |
| SPDR SER TR | 78464A870 | S&P BIOTECH | 4,300,000 | $408,027,000 | dollars as filed | |
| BIOMARIN PHARMACEUTICAL INC | 09061G101 | COM | 4,365,000 | $381,239,100 | dollars as filed | |
| AMICUS THERAPEUTICS INC | 03152W109 | COM | 27,400,000 | $322,772,000 | dollars as filed | |
| CEREVEL THERAPEUTICS HLDNG I | 15678U128 | COM | 7,555,555 | $319,373,310 | dollars as filed | |
| VIKING THERAPEUTICS INC | 92686J106 | COM | 3,590,000 | $294,380,000 | dollars as filed | |
| ARROWHEAD PHARMACEUTICALS IN | 04280A100 | COM | 8,555,555 | $244,688,873 | dollars as filed | |
| XENON PHARMACEUTICALS INC COM | 98420N105 | Stock | 5,666,666 | $243,949,971 | dollars as filed | |
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 5,775,000 | $228,921,000 | dollars as filed | |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 5,265,000 | $227,026,800 | dollars as filed | |
| IOVANCE BIOTHERAPEUTICS INC | 462260100 | COM | 11,700,000 | $173,394,000 | dollars as filed | |
| INTRA-CELLULAR THERAPIES INC | 46116X101 | COMMON STOCK | 2,475,000 | $171,270,000 | dollars as filed | |
| KYMERA THERAPEUTICS INC | 501575104 | COM | 3,888,888 | $156,333,298 | dollars as filed | |
| AVIDITY BIOSCIENCES INC COM | 05370A108 | Stock | 5,825,000 | $148,654,000 | dollars as filed | |
| MOONLAKE IMMUNOTHERAPEUTICS CLASS A ORD | 61559X104 | Stock | 2,580,000 | $129,593,400 | dollars as filed | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 4,222,222 | $100,488,884 | dollars as filed | |
| MACROGENICS INC | 556099109 | COM | 6,150,000 | $90,528,000 | dollars as filed | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 3,850,000 | $82,120,500 | dollars as filed | |
| AUTOLUS THERAPEUTICS PLC SPON | 05280R100 | COM | 12,345,678 | $78,765,426 | dollars as filed | |
| SPYRE THERAPEUTICS INC | 00773J202 | COM NEW | 1,839,138 | $69,758,504 | dollars as filed | |
| SOLENO THERAPEUTICS INC | 834203309 | COM | 1,625,000 | $69,550,000 | dollars as filed | |
| BIOCRYST PHARMACEUTICALS INC COM | 09058V103 | Stock | 13,050,000 | $66,294,000 | dollars as filed | |
| OCULAR THERAPEUTIX INC | 67576A100 | COM | 7,148,936 | $65,055,318 | dollars as filed | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 18,650,000 | $53,525,500 | dollars as filed | |
| Tourmaline Bio Inc | 89157D105 | Common Stock | 2,222,222 | $50,888,884 | dollars as filed | |
| ROIVANT SCIENCES LTD | G76279101 | SHS | 4,651,162 | $49,023,247 | dollars as filed | |
| ALNYLAM PHARMACEUTICALS INC COM | 02043Q107 | Stock | 300,000 | $44,835,000 | dollars as filed | |
| MANNKIND CORP COM NEW | 56400P706 | Stock | 9,000,000 | $40,770,000 | dollars as filed | |
| MERUS N V | N5749R100 | COM | 888,888 | $40,026,627 | dollars as filed | |
| VAXCYTE INC COM | 92243G108 | Stock | 575,000 | $39,278,250 | dollars as filed | |
| ULTRAGENYX PHARMACEUTICAL IN | 90400D108 | COM | 830,000 | $38,752,700 | dollars as filed | |
| MARINUS PHARMACEUTICALS INC | 56854Q200 | COM NEW | 4,140,607 | $37,431,087 | dollars as filed | |
| ROCKET PHARMACEUTICALS INC | 77313F106 | COM | 1,260,900 | $33,968,646 | dollars as filed | |
| MONTE ROSA THERAPEUTICS INC | 61225M102 | COM | 4,535,000 | $31,971,750 | dollars as filed | |
| CG ONCOLOGY INC | 156944100 | COMMON STOCK | 700,000 | $30,730,000 | dollars as filed | |
| CRISPR THERAPEUTICS AG NAMEN AKT | H17182108 | Stock | 419,580 | $28,598,573 | dollars as filed | |
| VERRICA PHARMACEUTICALS INC | 92511W108 | COM | 3,999,999 | $23,679,994 | dollars as filed | |
| KYVERNA THERAPEUTICS INC | 501976104 | COMMON STOCK | 475,000 | $11,799,000 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 2,849,402 | $6,667,601 | dollars as filed | |
| ADVERUM BIOTECHNOLOGIES INC | 00773U207 | COM NEW | 416,666 | $5,891,657 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-24-061613 | this filing | 2024-05-15 | acceptance time not in the bulk data set |